Safe handling and administration of antineoplastic chemotherapy

Journal of Infusion Nursing

Volumn 32, Issue 1, 2009, Pages 23-32

  Eisenberg, Seth ^a,b  

^a Infusion Services   (United States)

^b SEATTLE CANCER CARE ALLIANCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; BUSULFAN; CARMUSTINE; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; MELPHALAN; MITOMYCIN; MITOXANTRONE; THIOTEPA; ANTINEOPLASTIC AGENT;

ALLERGIC REACTION; ALOPECIA; ANOREXIA; CANCER CHEMOTHERAPY; CARCINOGENIC ACTIVITY; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG CONTAMINATION; DYSPNEA; DYSURIA; EYE IRRITATION; FEVER; HEADACHE; HEALTH CARE PERSONNEL; INFERTILITY; LONG TERM EXPOSURE; MALAISE; NAUSEA; NURSING PRACTICE; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROTECTIVE CLOTHING; RASH; REVIEW; SYNCOPE; THORAX PAIN; VOMITING; ARTICLE; HUMAN; NEOPLASM; NURSING; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HEALTH; PRACTICE GUIDELINE;

ANTINEOPLASTIC AGENTS; GUIDELINE ADHERENCE; HUMANS; NEOPLASMS; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HEALTH;

EID: 61749087906     PISSN: 15331458     EISSN: None     Source Type: Journal    
DOI: 10.1097/NAN.0b013e31819246e0     Document Type: Review

References (59)

1. Connor TH. Hazardous anticancer drugs in health care: environmental exposure assessment. Ann N Y Acad Sci. 2006;1076:615-623.
2. Sessink PJ, Bos RP. Drugs hazardous to healthcare workers. Evaluation of methods for monitoring occupational exposure to cytostatic drugs. Drug Saf. 1999;20(4):347-359.
3. National Institute for Occupational Safety and Health. Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in the Health Care Setting. Washington, DC: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health; 2004. NIOSH Publication No. 2004-165.
4. Polovich M, White JM, Kelleher LO, eds. Chemotherapy and Biotherapy Guidelines and Recommendations for Practice. 2nd ed. Pittsburgh, PA: Oncology Nursing Society; 2005.
5. American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. Am J Health Syst Pharm. 2006;63:1172-1193.
6. Connor TH, McDiarmid MA. Preventing occupational exposures to antineoplastic drugs in health care settings. CA Cancer J Clin. 2006;56(6):354-365.
7. Falck K, Gröhn P, Sorsa M, et al. Mutagenicity in urine from nurses handling cytostatic drugs. Lancet. 1979;1(8128):1250-1251.
8. Anderson RW, Puckett WH Jr, Dana WJ, et al. Risk of handling injectable antineoplastic agents. Am J Hosp Pharm. 1982;39(11): 1881-1887.
9. Sotaniemi EA, Sutinen S, Arranto AJ, et al. Liver damage in nurses handling cytostatic agents. Acta Med Scand. 1983;214:3-181.
10. American Society of Hospital Pharmacists. ASHP technical assistance bulletin on handling cytotoxic drugs in hospitals. Am J Health Syst Pharm. 1985;42:131-137.
11. Nguyen TV, Theiss JC, Matney TS. Exposure of pharmacy personnel to mutagenic antineoplastic drugs. Cancer Res. 1982; 42(11):4792-4796.
12. Labuhn K, Valanis B, Schoeny R, Loveday K, Vollmer W. Nurses' and pharmacists' exposure to antineoplastic drugs: findings from industrial hygiene scans and urine mutagenicity tests. Cancer Nurs. 1998;21:2-79.
13. Everson RB, Ratcliffe JM, Flack PM, Hoffman DM, Watanabe AS. Detection of low levels of urinary mutagen excretion by chemotherapy workers which was not related to occupational drug exposures. Cancer Res. 1985;45(12, pt 1):6487-6497.
14. Baker ES, Connor TH. Monitoring occupational exposure to cancer chemotherapy drugs. Am J Health Syst Pharm. 1996;53:22-2713.
15. Newman NA, Valanis BG, Schoeny RS, Hee SQ. Urinary biological monitoring markers of anticancer drug exposure in oncology nurses. Am J Public Health. 1994;84:5-852.
16. DesRoches P. Cytotoxic drug handlers-monitoring in the occupational health setting. AAOHN J. 2003;51:3-106.
17. Cavallo D, Ursini CL, Perniconi B, et al. Evaluation of genotoxic effects induced by exposure to antineoplastic drugs in lymphocytes and exfoliated buccal cells of oncology nurses and pharmacy employees. Mutat Res. 2005;587(1/2):45-51.
18. Pethran A, Schierl R, Hauff K, et al. Uptake of antineoplastic agents in pharmacy and hospital personnel. Part I: monitoring of urinary concentrations. Int Arch Occup Environ Health. 2003;76:1-5.
19. Fransman W, Peelen S, Hilhorst S, et al. Nurses with dermal exposure to antineoplastic drugs: reproductive outcomes. Epidemiology. 2007;18:1-112.
20. Valanis B, Vollmer WM, Steele P. Occupational exposure to antineoplastic agents: self-reported miscarriages and stillbirths among nurses and pharmacists. J Occup Environ Med. 1999;41:8-632.
21. Selevan SG, Lindbohm ML, Hornung RW, Hemminki K. A study of occupational exposure to antineoplastic drugs and fetal loss in nurses. N Engl J Med. 1985;313:19-1173.
22. Stücker I, Caillard JF, Collin R, et al. Risk of spontaneous abortion among nurses handling antineoplastic drugs. Scand J Work Environ Health. 1990;16:2-102.
23. Shortridge LA, Lemasters GK, Valanis B, Hertzberg V. Menstrual cycles in nurses handling antineoplastic drugs. Cancer Nurs. 1995;18:6-439.
24. Saurel-Cubizolles MJ, Job-Spira N, Estryn-Behar M. Ectopic pregnancy and occupational exposure to antineoplastic drugs. Lancet. 1993;341(8854):1169.
25. Valanis B, Vollmer W, Labuhn K, Glass A. Occupational exposure to antineoplastic agents and self-reported infertility among nurses and pharmacists. J Occup Environ Med. 1997;39:6-574.
26. Martin S. The adverse health effects of occupational exposure to hazardous drugs. Community Oncol. 2005;2:5-397.
27. Vanchieri C. Health hazard to community practice nurses: the "big worry." Community Oncol. 2005;2:3-277.
28. Valanis BG, Vollmer WM, Labuhn KT, Glass AG. Acute symptoms associated with antineoplastic drug handling among nurses. Cancer Nurs. 1993;16:4-288.
29. Blair A, Zheng T, Linos A. Occupation and leukemia: a population-based case-control study in Iowa and Minnesota. Am J Ind Med. 2001;40:1-3.
30. Connor TH, Anderson RW, Sessink PJ, Broadfield L, Power LA. Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States. Am J Health Syst Pharm. 1999;56:14-1427.
31. Connor TH, Sessink PJ, Harrison BR, et al. Surface contamination of chemotherapy drug vials and evaluation of new vial-cleaning techniques: results of three studies. Am J Health Syst Pharm. 2005;62:5-475.
32. Hedmer M, Georgiadi A, Bremberg ER, Jönsson BA, Eksborg S. Surface contamination of cyclophosphamide packaging and surface contamination with antineoplastic drugs in a hospital pharmacy in Sweden. Ann Occup Hyg. 2005;49:7-629.
33. Connor TH, Anderson RW, Sessink PJ, Spivey SM. Effectiveness of a closed-system device in containing surface contamination with cyclophosphamide and ifosfamide in an i.v. admixture area. Am J Health Syst Pharm. 2002;59:1-68.
34. Del Gaudio D, Menonna-Quinn D. Chemotherapy. Potential occupational hazards. Am J Nurs. 1998;98:11-59.
35. McDevitt JJ, Lees PS, McDiarmid MA. Exposure of hospital pharmacists and nurses to antineoplastic agents. J Occup Med. 1993;35:1-57.
36. Ben-Ami S, Shaham J, Rabin S, Melzer A, Ribak J. The influence of nurses' knowledge, attitudes, and health beliefs on their safe behavior with cytotoxic drugs in Israel. Cancer Nurs. 2001;24:3-192.
37. McDonald GB. Management of hepatic disease following haematopoietic cell transplant [review]. Aliment Pharmacol Ther. 2006;24:3-441.
38. Larson RR, Khazaeli MB, Dillon HK. Monitoring method for surface contamination caused by selected antineoplastic agents. Am J Health Syst Pharm. 2002;59:3-270.
39. Sessink PJ, Van de Kerkhof MC, Anzion RB, Noordhoek J, Bos RP. Environmental contamination and assessment of exposure to antineoplastic agents by determination of cyclophosphamide in urine of exposed pharmacy technicians: is skin absorption an important exposure route? Arch Environ Health. 1994;49:3-165.
40. National Institute for Occupational Safety and Health. Medical Surveillance for Health Care Workers Exposed to Hazardous Drugs. Cincinnati, OH: Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health; 2007:1-4.
41. Rekhadevi PV, Sailaja N, Chandrasekhar M, Mahboob M, Rahman MF, Paramjit Grover. Genotoxicity assessment in oncology nurses handling anti-neoplastic drugs. Mutagenesis. 2007;22:6-395.
42. Sottani C, Tranfo G, Faranda P, Minoia C. Highly sensitive highperformance liquid chromatography/selective reaction monitoring mass spectrometry method for the determination of cyclophosphamide and ifosfamide in urine of health care workers exposed to antineoplastic agents. Rapid Commun Mass Spectrom. 2005;19:19-2794.
43. Turci R, Sottani C, Ronchi A, Minoia C. Biological monitoring of hospital personnel occupationally exposed to antineoplastic agents. Toxicol Lett. 2002;134(1-3):57-64.
44. Harrison BR, Kloos MD. Penetration and splash protection of six disposable gown materials against fifteen antineoplastic drugs. J Oncol Pharm Pract. 1999;5:2-61.
45. Polovich M, Blecher CS, Glynn-Tucker EM, McDiarmid M, Newton SA, eds. Safe Handling of Hazardous Drugs. Pittsburgh, PA: Oncology Nursing Society; 2003.
46. Connor TH. Permeability of nitrile rubber, latex, polyurethane, and neoprene gloves to 18 antineoplastic drugs. Am J Health Syst Pharm. 1999;56:23-2450.
47. Klein M, Lambov N, Samev N, Carstens G. Permeation of cytotoxic formulations through swatches from selected medical gloves. Am J Health Syst Pharm. 2003;60:10-1006.
48. Gross ER, Groce DF. An evaluation of nitrile gloves as an alternative to natural rubber latex for handling chemotherapeutic agents. J Oncol Pharm Pract. 1998;4:165-168.
49. Meijster T, Fransman W, Veldhof R, Kromhout H. Exposure to antineoplastic drugs outside the hospital environment. Ann Occup Hyg. 2006;50:7-657.
50. Martin S, Larson E. Chemotherapy-handling practices of outpatient and office-based oncology nurses. Oncol Nurs Forum. 2003;30:4-575.
51. Mahon SM, Casperson DS, Yackzan S, et al. Safe handling practices of cytotoxic drugs: the results of a chapter survey. Oncol Nurs Forum. 1994;21:7-1157.
52. Nieweg RM, de Boer M, Dubbleman RC, et al. Safe handling of antineoplastic drugs. Results of a survey. Cancer Nurs. 1994; 17(6):501-511.
53. Fransman W, Peelen S, Hilhorst S, et al. A pooled analysis to study trends in exposure to antineoplastic drugs among nurses. Ann Occup Hyg. 2007;51:3-231.
54. Vandenbroucke J, Robays H. How to protect environment and employees against cytotoxic agents, the UZ Ghent experience. J Oncol Pharm Pract. 2001;6:4-146.
55. Fransman W, Vermeulen R, Kromhout H. Occupational dermal exposure to cyclophosphamide in Dutch hospitals: a pilot study. Ann Occup Hyg. 2004;48:3-237.
56. US Pharmacopeia. Pharmaceutical compounding-sterile preparations: revision to general . In: The USP Pharmacists' Pharmacopeia. 2nd ed. Rockville, MD: US Pharmacopeia; 2008. pp 1-61.
57. Wick C, Slawson MH, Jorgenson JA, Tyler LS. Using a closedsystem protective device to reduce personnel exposure to antineoplastic agents. Am J Health Syst Pharm. 2003;60(22):2314- 2320.
58. Harrison BR, Peters BG, Bing MR. Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed-system drug transfer device versus standard preparation techniques. Am J Health Syst Pharm. 2006;63:18-1736.
59. Johnson EG, Janosik JE. Manufacturers' recommendations for handling spilled antineoplastic agents. Am J Health Syst Pharm. 1989;46:2-318.